Form 4: Serina Therapeutics Director Steven Mintz Reports Stock Transactions
SEC Form 4
Director Steven Mintz reports acquisition and disposal of Serina Therapeutics (SER) common stock.
Summary
- On June 21, 2024, Steven Mintz, a director of Serina Therapeutics, acquired 5,000 shares of common stock at $9.50 per share.
- On June 25, 2024, Mintz acquired 2,600 shares of common stock at $9 per share.
- Following these transactions, Mintz directly owns 10,907 shares of common stock.
- Mintz also reports indirect ownership of 9,900 shares through his spouse and 1,240 shares each through two adult children.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock transactions. The director's purchase could be seen as slightly positive, but it's not a major indicator.
Positives
- Director's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders.
Stakeholder Impact
- The transactions may have a minor impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Steven Mintz acquired 5,000 shares of common stock at $9.50 per share. |
| 06/25/2024 | Steven Mintz acquired 2,600 shares of common stock at $9 per share. |
| 06/27/2024 | Date of report submission. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.